Schizophrenia drug showdown: which pill spares your Cells' power plants?

NCT ID NCT06236451

Completed Knowledge-focused Sponsor: All India Institute of Medical Sciences, Bhubaneswar Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study compared two schizophrenia medications, aripiprazole and risperidone, in 60 patients to see how they affect mitochondria—the energy factories inside cells. Researchers measured changes in mitochondrial activity and related blood markers over 12 weeks. The goal was to understand if these drugs cause cell energy problems that might lead to side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aripiprazole and Risperidone
What this could lead to: If successful, this could help explain why some antipsychotics cause side effects like movement problems, potentially guiding safer treatment choices.
What could go wrong: This is a small, completed study measuring biological markers, not clinical outcomes. Results may not change treatment or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inborn mitochondrial metabolism disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

All India Institute of Medical Sciences (AIIMS)

Bhubaneswar, Odisha, 751019, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.